Additional file 6: Supplementary Figure S5. The mutation allele fre - quencies of other mutations in DNA level and RNA level between primary tumor and recurrent tumor.Additional file 7: Supplementary Figure S6. The heatmap analysis of immune cell infiltration by transcriptomic data. Additional file 8: Supplementary Figure S7. The profiling of other mutations detected in matched preoperative plasma. Additional file 9: Supplementary Figure S8. The time-course demon- stration of quantified levels of treated neoantigen mutations and other somatic mutations in patient N06(A) and N13(B), respectively. The small picture displays the dynamics of the average of mutation allele frequen- cies in treated neoantigen mutations and other somatic mutations during neoantigen vaccination and follow up. Additional file 10: Supplementary Table S1. Baseline clinical character - istics between enrolled patients and PSM case-control patients. Additional file 11: Supplementary Table S2. The detailed HLA type and neoantigen sequence for neoantigen vaccine preparation of each enrolled patients. Additional file 12: Supplementary Table S3. Treatment-related adverse events in all enrolled patients. Additional file 13: Supplementary Table S4. The dynamics of routine blood and biochemical tests in all enrolled patients during neoantigen vaccinations. Additional file 14: Supplementary Table S5. The dynamic change in proportions of peripheral blood T lymphocyte subsets and serum levels of 6 cytokines in all enrolled patients during neoantigen vaccinations. Additional file 15: Supplementary Table S6. New neoantigen muta- tions identified in recurrent tumor. Additional file 16: Supplementary Table S7. The detailed ctDNA fre - quency of neoantigen mutations and other somatic mutations in enrolled patients during clinical course. Acknowledgments We appreciate the help of neoantigen screening and data analysis by the P&PMed Biotechnology Co.Ltd.(Shanghai, China). Conflict of interest No potential conflicts of interest were disclosed. Authors’ contributions ZC, XS, YZ, and XL conceived and designed the experiments. ZC, LQ, ZL, XL, XQ, FW, YZ and LL performed the experiments. XS, ZL, HC and YW analyzed the data. ZL, GC performed bioinformatic analyses. ZC, XS, YZ and XL wrote the manuscript. All authors have read and approved the final manuscript. Funding This work was supported by regional development project of Fujian Province [grant number 2019Y3001], the Scientific Foundation of the Fuzhou Health Commission [grant number 2019-S-wt3]. Availability of data and materials The data used to support the findings of this study are included within the article. The raw sequencing data reported in this article has been deposited at Big Data center (Nucleic Acids Res 2018), under the accession number of HRA000096 that are publicly accessible at http:// bigd. big.